LRRK2 inhibitors
US11780851B2 · kind B2 · utility
2Cited by
0References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 26, 2022 |
| Grant date | Oct 10, 2023 |
| Priority date | — |
| Expiry date | Oct 26, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/05
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention is directed to compounds of formula I The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Parkinson's disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.